# AstraZeneca (South Korea)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/astrazeneca-south-korea/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 47.5 |
| Citations | 54,221 |
| City | Seoul |
| Country | KR |
| Description | AstraZeneca (South Korea) is a research organisation in Seoul, KR. OpenAlex records 1,052 works and 54,221 citations for it. 560 researchers list it as their most recent affiliation. |
| Homepage | https://www.astrazeneca.com |
| OpenAlex ID | https://openalex.org/I4210092243 |
| Researchers | 560 |
| ROR ID | https://ror.org/00h1xaa75 |
| Type | company |
| Works | 1,052 |

## University papers

Showing 12 of 27.

- [A lexicon for endoscopic adverse events: report of an ASGE workshop](https://scholariq.org/papers/a-lexicon-for-endoscopic-adverse-events-report-of-an-asge-workshop/)
- [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M](https://scholariq.org/papers/acquired-egfr-c797s-mutation-mediates-resistance-to-azd9291-in-non-small-cell/)
- [Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/association-between-plasma-genotyping-and-outcomes-of-treatment-with-osimertinib/)
- [Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity](https://scholariq.org/papers/preclinical-comparison-of-osimertinib-with-other-egfr-tkis-in-egfr-mutant-nsclc/)
- [Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib](https://scholariq.org/papers/assessment-of-resistance-mechanisms-and-clinical-implications-in-patients-with-i/)
- [Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-as-first-line-treatment-of-i-egfr-i-mutation-positive-advanced-non/)
- [Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes](https://scholariq.org/papers/effect-of-dapagliflozin-on-worsening-heart-failure-and-cardiovascular-death-in/)
- [Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia](https://scholariq.org/papers/submucosal-endoscopic-esophageal-myotomy-a-novel-experimental-approach-for-the/)
- [EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291](https://scholariq.org/papers/egfr-mutation-detection-in-ctdna-from-nsclc-patient-plasma-a-cross-platform/)
- [Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.](https://scholariq.org/papers/turnover-of-cyclin-e-by-the-ubiquitin-proteasome-pathway-is-regulated-by-cdk2/)
- [Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis](https://scholariq.org/papers/why-do-scp-sglt2-scp-inhibitors-reduce-heart-failure-hospitalization-scp-a-scp/)
- [TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer](https://scholariq.org/papers/tatton-a-multi-arm-phase-ib-trial-of-osimertinib-combined-with-selumetinib/)

## University researchers

- [Kenneth S. Thress](https://scholariq.org/researchers/kenneth-s-thress/)
- [David W. Boulton](https://scholariq.org/researchers/david-w-boulton/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.